Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Determinants and Monitoring of Response to disease-modifying therapy for Transthyretin Amyloidosis Cardiomyopathy: The ATTR-CM study
EF 2021-22
Résumé
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a heart muscle disease with only a 3.6-year median survival time from diagnosis without treatment. ATTR-CM is caused by amyloid plaque buildup in the myocardial interstitium from misfolded transthyretin proteins. Awareness of this disease has dramatically improved with approval of the novel disease modifying therapy tafamidis, a medication approved by Health Canada in 2020 for treatment of ATTR-CM. However, significant knowledge gaps remain and predictors of response to therapy are poorly understood. There have also been significant advancements in clinical care since the ATTR-ACT study, a clinical trial that assessed tafamidis for ATTR-CM treatment. Techniques for non-invasive diagnosis have now improved and facilitate increased rate of diagnosis. Tafamidis is also the most expensive cardiovascular medication, with a list price of approximately $200,000 per year per patient. Eligibility criteria defined by Health Canada for tafamidis therapy initiation do not optimally reflect the current population of patients. The primary objective of this study is to develop an evidence-based approach for predicting response to therapy by evaluating a cohort of ATTR-CM patients treated with tafamidis. The secondary objective is to determine the magnitude and timing of changes in monitoring parameters such as symptom burden, laboratory biomarkers, and cardiac imaging variables. Predicting response to therapy is crucial in improving existing eligibility criteria and clinical usage of tafamidis. The study will help guide future treatment, bridge gaps in the optimal management of ATTR-CM and reduce healthcare expenditures by identifying those most likely to derive benefit from this expensive therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466555
Name
Shahi Karan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determinants and Monitoring of Response to disease-modifying therapy for Transthyretin Amyloidosis Cardiomyopathy: The ATTR-CM study
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Baseline Predictors Of Response; Cardiac Imaging; Evidence Based Approach; Heart Failure; Laboratory Biomarkers; Response To Therapy; Retrospective Cohort Study; Tafamidis Treatment/Therapy; Therapy Clinical Criteria; Transthyretin Amyloidosis Cardiomyopathy (Attr-Cm)
Abstract
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a heart muscle disease with only a 3.6-year median survival time from diagnosis without treatment. ATTR-CM is caused by amyloid plaque buildup in the myocardial interstitium from misfolded transthyretin proteins. Awareness of this disease has dramatically improved with approval of the novel disease modifying therapy tafamidis, a medication approved by Health Canada in 2020 for treatment of ATTR-CM. However, significant knowledge gaps remain and predictors of response to therapy are poorly understood. There have also been significant advancements in clinical care since the ATTR-ACT study, a clinical trial that assessed tafamidis for ATTR-CM treatment. Techniques for non-invasive diagnosis have now improved and facilitate increased rate of diagnosis. Tafamidis is also the most expensive cardiovascular medication, with a list price of approximately $200,000 per year per patient. Eligibility criteria defined by Health Canada for tafamidis therapy initiation do not optimally reflect the current population of patients. The primary objective of this study is to develop an evidence-based approach for predicting response to therapy by evaluating a cohort of ATTR-CM patients treated with tafamidis. The secondary objective is to determine the magnitude and timing of changes in monitoring parameters such as symptom burden, laboratory biomarkers, and cardiac imaging variables. Predicting response to therapy is crucial in improving existing eligibility criteria and clinical usage of tafamidis. The study will help guide future treatment, bridge gaps in the optimal management of ATTR-CM and reduce healthcare expenditures by identifying those most likely to derive benefit from this expensive therapy.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shahi, Karan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~